Document Detail


Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121.
MedLine Citation:
PMID:  11839634     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Therapeutic angiogenesis is a new approach to treating ischemic heart disease, and the optimal method for assessing its efficacy is unclear. We used myocardial contrast echocardiography (MCE) to evaluate the therapeutic response to the angiogenic agent, vascular endothelial growth factor-121 (VEGF121). METHODS AND RESULTS: After placement of an ameroid constrictor (day 0) around the left anterior descending artery (LAD), dogs were given intracoronary VEGF121 protein (108 microg, n=6) or placebo (n=6) on days 7 and 21, and subcutaneous VEGF121 (1 mg) or placebo on days 8 to 20 and 22 to 27. On day 48, MCE was performed during rest and dobutamine stress. Videointensity (y) and pulsing interval (t) were fit to an exponential model (y=A[1-e(-beta(t))]) used to derive indices of red cell velocity (beta) and capillary area (A), and parameters were compared with radiolabeled microsphere flow data. VEGF(121) treatment resulted in higher resting left anterior descending artery/left circumflex flow ratio compared with placebo (P<0.03) and improved collateral flow reserve. Beta was 0.94+/-0.37 in VEGF121 dogs versus 0.38+/-0.31 in controls (P<0.02), with the greatest difference in the endocardium. The parameter A was comparable in both groups, suggesting that microvascular changes did not alter capillary cross-sectional area, and histology indicated a trend toward higher arteriolar density in VEGF121-treated animals. CONCLUSIONS: VEGF121 protein improves collateral flow and reserve. MCE can evaluate the transmural location and structural and functional responses of the microvasculature to angiogenic interventions.
Authors:
Flordeliza S Villanueva; Judith A Abraham; George F Schreiner; Melissa Csikari; David Fischer; James D Mills; Ute Schellenberger; Bryan J Koci; Joon S Lee
Related Documents :
7532374 - Protamine inhibits coronary collateral development in a canine model of repetitive coro...
8172054 - Adenosine-induced heterogeneous perfusion accompanies myocardial ischemia in the presen...
15173714 - Development of biologic coronary artery bypass grafting in a rabbit model: revival of a...
20435184 - Collateral pressure and flow in acute myocardial infarction with total coronary occlusi...
1417374 - Stroke complicating acute myocardial infarction. a meta-analysis of risk modification b...
2468944 - Effects of angiotensin ii and captopril on inducible sustained ventricular tachycardia ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  105     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-02-12     Completed Date:  2002-02-22     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  759-65     Citation Subset:  AIM; IM    
Affiliation:
Cardiovascular Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pa 15213, USA. villanuevafs@msx.upmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Flow Velocity / drug effects
Collateral Circulation / drug effects
Coronary Circulation / drug effects
Coronary Disease / drug therapy*,  ultrasonography*
Disease Models, Animal
Dogs
Echocardiography*
Electrocardiography
Endothelial Growth Factors / pharmacology*
Heart / drug effects
Lymphokines / pharmacology*
Microcirculation / drug effects*,  ultrasonography*
Myocardial Revascularization
Myocardium / pathology
Predictive Value of Tests
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Grant Support
ID/Acronym/Agency:
R29HL58865/HL/NHLBI NIH HHS; R44 HL58403/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Endothelial Growth Factors; 0/Lymphokines; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhib...
Next Document:  Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in...